Bukwang Pharmaceutical Co., Ltd. (003000.KS)
KRW 4745.0
(-1.35%)
KRW 4745.0
(-1.35%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -457.67 KRW | -637.34% |
| 2022 | -62.07 KRW | -51.95% |
| 2021 | -40.85 KRW | 72.25% |
| 2020 | -147.23 KRW | -42.05% |
| 2019 | -103.65 KRW | -103.97% |
| 2018 | 2613.89 KRW | 1515.11% |
| 2017 | 161.84 KRW | -27.16% |
| 2016 | 222.20 KRW | -37.27% |
| 2015 | 354.19 KRW | 5.2% |
| 2014 | 336.67 KRW | 22.33% |
| 2013 | 275.21 KRW | 17.66% |
| 2012 | 233.91 KRW | 150.39% |
| 2011 | 93.42 KRW | -75.16% |
| 2010 | 376.05 KRW | -1.14% |
| 2009 | 380.37 KRW | -10.13% |
| 2008 | 423.24 KRW | -9.27% |
| 2007 | 466.46 KRW | 65.02% |
| 2006 | 282.67 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q3 | 1.45 KRW | 103.96% |
| 2024 Q1 | -37.37 KRW | 76.31% |
| 2024 Q2 | -50.53 KRW | -35.22% |
| 2023 Q1 | -82.83 KRW | -448.46% |
| 2023 FY | - KRW | -637.34% |
| 2023 Q2 | 7.06 KRW | 108.52% |
| 2023 Q3 | -235.35 KRW | -3433.57% |
| 2023 Q4 | -157.72 KRW | 32.98% |
| 2022 Q2 | -6.16 KRW | 80.12% |
| 2022 Q1 | -30.98 KRW | -210.64% |
| 2022 FY | - KRW | -51.95% |
| 2022 Q3 | -28.67 KRW | -365.42% |
| 2022 Q4 | 23.77 KRW | 182.91% |
| 2021 FY | - KRW | 72.25% |
| 2021 Q1 | -52.00 KRW | -125.11% |
| 2021 Q3 | 10.00 KRW | 350.0% |
| 2021 Q2 | -4.00 KRW | 92.31% |
| 2021 Q4 | 28.00 KRW | 180.0% |
| 2020 Q1 | -13.64 KRW | -117.07% |
| 2020 Q3 | -90.91 KRW | -576.22% |
| 2020 Q4 | -23.10 KRW | 74.59% |
| 2020 Q2 | 19.09 KRW | 239.96% |
| 2020 FY | - KRW | -42.05% |
| 2019 Q3 | -48.48 KRW | 70.06% |
| 2019 Q4 | 79.91 KRW | 264.83% |
| 2019 Q1 | 35.50 KRW | 147.08% |
| 2019 FY | - KRW | -103.97% |
| 2019 Q2 | -161.90 KRW | -556.06% |
| 2018 FY | - KRW | 1515.11% |
| 2018 Q3 | 1583.08 KRW | 5559.92% |
| 2018 Q4 | -75.40 KRW | -104.76% |
| 2018 Q2 | 27.97 KRW | -30.01% |
| 2018 Q1 | 39.96 KRW | 304.86% |
| 2017 Q3 | 48.44 KRW | 86.09% |
| 2017 Q1 | 93.24 KRW | 362.5% |
| 2017 Q2 | 26.03 KRW | -72.08% |
| 2017 FY | - KRW | -27.16% |
| 2017 Q4 | 9.87 KRW | -79.62% |
| 2016 Q3 | -15.14 KRW | -127.53% |
| 2016 FY | - KRW | -37.27% |
| 2016 Q2 | 55.00 KRW | -73.67% |
| 2016 Q4 | -35.52 KRW | -134.61% |
| 2016 Q1 | 208.88 KRW | 252.48% |
| 2015 Q4 | 59.26 KRW | -58.32% |
| 2015 Q2 | 61.00 KRW | -21.77% |
| 2015 FY | - KRW | 5.2% |
| 2015 Q3 | 142.19 KRW | 133.1% |
| 2015 Q1 | 77.98 KRW | 17.32% |
| 2014 Q4 | 66.47 KRW | -26.88% |
| 2014 Q2 | 74.22 KRW | -23.93% |
| 2014 Q1 | 97.57 KRW | 82.0% |
| 2014 Q3 | 90.90 KRW | 22.47% |
| 2014 FY | - KRW | 22.33% |
| 2013 Q4 | 53.61 KRW | -44.9% |
| 2013 FY | - KRW | 17.66% |
| 2013 Q2 | 68.70 KRW | 12.33% |
| 2013 Q1 | 61.16 KRW | -31.9% |
| 2013 Q3 | 97.30 KRW | 41.63% |
| 2012 Q2 | 43.12 KRW | 1168.24% |
| 2012 Q3 | 97.96 KRW | 127.18% |
| 2012 FY | - KRW | 150.39% |
| 2012 Q1 | 3.40 KRW | 0.0% |
| 2012 Q4 | 89.81 KRW | -8.32% |
| 2011 Q3 | 59.43 KRW | -30.39% |
| 2011 Q2 | 85.37 KRW | -45.39% |
| 2011 Q1 | 156.33 KRW | 104.73% |
| 2011 FY | - KRW | -75.16% |
| 2010 FY | - KRW | -1.14% |
| 2010 Q3 | 84.29 KRW | 42.7% |
| 2010 Q4 | 76.36 KRW | -9.41% |
| 2010 Q2 | 59.07 KRW | -34.66% |
| 2010 Q1 | 90.41 KRW | -16.89% |
| 2009 Q4 | 108.78 KRW | 17.06% |
| 2009 FY | - KRW | -10.13% |
| 2009 Q1 | 193.35 KRW | 111.33% |
| 2009 Q2 | 88.25 KRW | -54.36% |
| 2009 Q3 | 92.93 KRW | 5.3% |
| 2008 FY | - KRW | -9.27% |
| 2008 Q2 | 113.46 KRW | -42.76% |
| 2008 Q3 | 103.02 KRW | -9.2% |
| 2008 Q4 | 91.49 KRW | -11.19% |
| 2008 Q1 | 198.23 KRW | 46.52% |
| 2007 Q2 | 91.98 KRW | 0.0% |
| 2007 Q4 | 135.29 KRW | 9.85% |
| 2007 FY | - KRW | 65.02% |
| 2007 Q3 | 123.16 KRW | 33.9% |
| 2006 FY | - KRW | 0.0% |